Novo Nordisk Stock Plummets After Ozempic-Maker's Alzheimer's Drug Trial Fails
The company said the weight loss and diabetes treatment drug failed to show any significant reduction in the progression of Alzheimer's disease in patients.
(Forbes, 2025-11-24T12:39:26Z)